renal%20cancer
RENAL CANCER

Renal cancer is the disease in which certain tissues of the kidney starts to grow uncontrollably and form a tumor.

It is also called as renal adenocarcinoma or hypernephroma.

Classic triad of symptoms are flank pain, palpable abdominal mass and gross hematuria.

Renal%20cancer Management

Monitoring

  • Management option for patients with stage T1 kidney tumor 
    • Patients with tumors <2 cm, T1a masses ≤4 cm with predominantly cystic component, or clinical stage T1 masses at risk for death or morbidity if managed aggressively
  • May also be considered in select asymptomatic patients with favorable-risk ccRCC 
  • The initial monitoring of tumor size by serial abdominal imaging [eg ultrasound (UTZ), computed tomography (CT) or magnetic resonance imaging (MRI) scan] with timely intervention reserved for tumors showing clinical progression during follow-up
  • Alternative strategy for elderly patients, patients with short life expectancy, and significant comorbidities
  • May utilize renal biopsy for surveillance and should include periodic metastatic survey including hematologic exams and chest imaging if with tumor growth

Follow Up

Stage I (pT1a)

During Active Surveillance

  • Annual history and physical exam
  • Annual laboratory tests as clinically indicated
  • Abdominal computed tomography (CT) or magnetic resonance imaging (MRI) within 6 months of surveillance initiation, then CT, MRI, or ultrasound (UTZ) at least annually
    • MRI with contrast if not contraindicated
  • Annual and baseline chest x-ray or CT to assess for pulmonary metastases
  • Biopsy may be considered at start of surveillance or during follow-up as clinically indicated

After Ablative Techniques

  • Annual history and physical exam
  • Annual laboratory tests as clinically indicated
  • Abdominal CT or MRI at 3-6 months after ablative therapy unless otherwise contraindicated then CT, MRI or UTZ annually for 5 years or longer as clinically indicated
  • Annual chest x-ray or CT to assess for patients with biopsy-positive RCC, nondiagnostic biopsies, or even without prior biopsy

Stage I (pT1a) and (pT1b)

After Partial or Radical Nephrectomy

  • Annual history and physical exam
  • Annual laboratory tests as clinically indicated
  • Baseline abdominal CT or MRI or UTZ within 3-12 months post-surgery then annually for 3 years or longer as clinically indicated
  • Chest x-ray or CT annually for at least 5 years, then as clinically indicated
    • May decrease interval or technique modality if with positive margins or adverse pathologic features

Stage II or III

After Radical Nephrectomy

  • History and physical exam every 3-6 months for 3 years, then annually up to 5 years and then as clinically indicated thereafter
  • Comprehensive metabolic panel and other test as indicated every 6 months for 2 years, then annually up to 5 years then as clinically indicated thereafter
  • Baseline abdominal CT or MRI within 3-6 months, then CT, MRI or UTZ every 3-6 months for at least 3 years then annually up to 5 years; as clinically indicated thereafter
  • Baseline chest CT within 3-6 months after radical nephrectomy with continued imaging (CT or chest x-ray) every 3-6 months for at least 3 years and then annually up to 5 years
    • May consider imaging beyond 5 years depending on patient characteristics and tumor risk factors
  • Pelvic imaging, CT or MRI of the head or MRI of spine, and bone scan, as clinically indicated

Relapsed or Stage IV and Surgically Unresectable Disease

  • History and physical exam every 6-16 weeks for patients receiving systemic therapy, or more frequently as clinically indicated and adjusted for the type of systemic therapy the patient is receiving
  • Required laboratory examinations based therapeutic agents being used
  • CT or MRI imaging to assess baseline pretreatment or prior to observation
  • May consider follow-up imaging every 6-16 weeks or as deemed appropriate based on patient's clinical status, rate of disease change and sites of active disease
  • Consider CT or MRI of the head, MRI of spine, and bone scan, as clinically indicated

After Adjuvant Therapy

  • Same follow-up instructions as stage II or III

Long-term Follow-up

  • Should be based on assessment of patient factors eg mortality, risk factors for RCC, performance status, patient preference
  • Annual history and physical exam for evaluation of metastasis risk or treatment sequelae
  • Annual laboratory test after surgery to evaluate renal function and glomerular filtration rate
  • May consider abdominal imaging with increasing intervals if with low but significant risk for metachronous tumors or late recurrences
  • May consider chest imaging in patients with high stage RCC and to increase intervals if with low but significant recurrence risk
Editor's Recommendations
Most Read Articles
6 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 06 Jul 2020
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 4 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.